Skip to main content

Study

Prescription of Monoclonal Antibodies Against Calcitonin Gene-Related Peptide for the Prophylaxis of Migraine in Austria: A Retrospective, Longitudinal Analysis of Nationwide Insurance Data

This large Austrian insurance-based study found that monoclonal antibodies targeting CGRP significantly reduced migraine frequency and health care ...

Study Credibility: Medium6.0/10Some supporting evidenceStudy has limitationsUse with caution
PublishedDec 2025Last reviewedFeb 2026
Email this

Summary

In plain language

This large Austrian insurance-based study found that monoclonal antibodies targeting CGRP significantly reduced migraine frequency and health care use. Benefits were consistent across age groups, including adults over 60.

Details

Use the full description to understand the study design, methods, and the limits of the findings.

A nationwide analysis in Austria found that patients treated with CGRP monoclonal antibodies experienced fewer migraine days and hospitalizations, confirming the safety and effectiveness of this therapy for migraine prevention.

Research Quality Score

Scored February 1, 2026 using rubric v6_2026-02-01.

Assessment

The study provides useful insights into the use of monoclonal antibodies for migraine prevention in older adults, but its retrospective design and potential biases limit the strength of its conclusions. It is relevant to seniors but should be interpreted with caution due to methodological limitations.

Category Breakdown

CategoryScoreRating
Study design5.0/10
Bias control4.0/10
Statistical methods6.0/10
Reporting completeness7.0/10
Conflicts & funding8.0/10
Replication5.0/10
Relevance to chosen population7.0/10
Journal Reliability8.0/10

Additional Notes

Future studies should aim for prospective designs with clear bias control methods to strengthen evidence quality.

Take the next step

Build a personalized plan using research-backed studies, conditions, and treatments.